OnKure Therapeutics, Inc.
OKURNASDAQHealthcare● Active
$4.40
+$0.21(+5.01%)
Market Cap$60163840
P/E Ratio—
52W High$5.38
52W Low$1.91
OnKure Therapeutics, Inc. (OKUR) Earnings: Dates, EPS & Revenue History
Quarterly EPS vs. estimates, revenue surprises, next earnings date, and analyst consensus.
OKUR · earnings · updated Jun 9, 2026
Latest Earnings
Q2 FY2026Report Date: May 5, 2026EPS Actual
-$1.11
Est. -$0.81 · -37.0%
Revenue
—
Est. $0.00B
Fiscal Period
Q2 FY2026
FY ends December
Report Date
May 5, 2026
After Market Close
▼ Miss EPS
OKUR reports quarterly as a NASDAQ-listed Biotechnology company. Fiscal year ends in December. Data: FMP · Updated hourly.
Next Earnings Date
Days Away
84
days
Expected Date
Sep 1, 2026
Fiscal Period
Q3 FY2026
Release Time
◌ Time TBD (Unconfirmed)EPS Est.
$93.32
Rev. $1001.5B
Days Away84
Expected DateSep 1, 2026
Fiscal PeriodQ3 FY2026
Release TimeTime TBD (Unconfirmed)
EPS Est.$93.32
Rev. Est.$1001.5B
EPS & Revenue vs. Estimates
Actual (Beat)
Actual (Miss)
Estimated
Earnings History
| Period | Report Date | EPS Est. | EPS Actual | EPS Surpr. | Revenue | Rev. Est. | Rev. Surpr. |
|---|---|---|---|---|---|---|---|
| ◌ Q3 FY2026 | Aug 11, 2026 | -$0.67 | — | — | — | $0.00B | — |
| ▼ Q2 FY2026 | May 5, 2026 | -$0.81 | -$1.11 | -37.0% | — | $0.00B | — |
| ▲ Q1 FY2026 | Mar 12, 2026 | -$1.15 | -$0.99 | +13.9% | — | $0.02B | — |
| ▲ Q4 FY2025 | Nov 6, 2025 | -$1.20 | -$1.09 | +9.2% | — | — | — |
| ▲ Q3 FY2025 | Aug 12, 2025 | -$1.23 | -$1.14 | +7.3% | — | — | — |
| ▲ Q2 FY2025 | May 6, 2025 | -$1.32 | -$1.19 | +9.8% | — | — | — |
| ▼ Q1 FY2025 | Mar 10, 2025 | -$0.86 | -$1.37 | -59.3% | — | — | — |
| ▼ Q4 FY2024 | Nov 7, 2024 | -$0.97 | -$1.10 | -13.4% | — | — | — |
Q3 FY2026
Aug 11, 2026
EPS Actual
—
EPS Est.
-$0.67
EPS Surpr.
—
Revenue
—
Q2 FY2026
May 5, 2026Miss
EPS Actual
-$1.11
EPS Est.
-$0.81
EPS Surpr.
-37.0%
Revenue
—
Q1 FY2026
Mar 12, 2026Beat
EPS Actual
-$0.99
EPS Est.
-$1.15
EPS Surpr.
+13.9%
Revenue
—
Q4 FY2025
Nov 6, 2025Beat
EPS Actual
-$1.09
EPS Est.
-$1.20
EPS Surpr.
+9.2%
Revenue
—
Q3 FY2025
Aug 12, 2025Beat
EPS Actual
-$1.14
EPS Est.
-$1.23
EPS Surpr.
+7.3%
Revenue
—
Q2 FY2025
May 6, 2025Beat
EPS Actual
-$1.19
EPS Est.
-$1.32
EPS Surpr.
+9.8%
Revenue
—
Q1 FY2025
Mar 10, 2025Miss
EPS Actual
-$1.37
EPS Est.
-$0.86
EPS Surpr.
-59.3%
Revenue
—
Q4 FY2024
Nov 7, 2024Miss
EPS Actual
-$1.10
EPS Est.
-$0.97
EPS Surpr.
-13.4%
Revenue
—
Analyst Estimates
Limited analyst coverage (fewer than 3 analysts). Estimates may not reflect market consensus.
EPS Estimates
| Period | Low | Consensus | High | # Analysts |
|---|---|---|---|---|
| Q4 FY2027 | $-0.48 | $-0.48 | $-0.48 | 1 |
| Q3 FY2027 | $-0.56 | $-0.56 | $-0.56 | 1 |
| Q2 FY2027 | $-0.75 | $-0.75 | $-0.75 | 1 |
| Q1 FY2027 | $-0.73 | $-0.73 | $-0.73 | 1 |
| Q4 FY2026 | $-0.67 | $-0.67 | $-0.67 | 1 |
| Q3 FY2026 | $-0.70 | $-0.64 | $-0.57 | 2 |
Revenue Estimates
| Period | Low | Consensus | High | # Analysts |
|---|---|---|---|---|
| Q4 FY2027 | $0.0B | $0.0B | $0.0B | 1 |
| Q3 FY2027 | $0.0B | $0.0B | $0.0B | 1 |
| Q2 FY2027 | $0.0B | $0.0B | $0.0B | 1 |
| Q1 FY2027 | $0.0B | $0.0B | $0.0B | 1 |
| Q4 FY2026 | $0.0B | $0.0B | $0.0B | 1 |
| Q3 FY2026 | $0.0B | $0.0B | $0.0B | 2 |
Earnings Price Reaction
Closing price one trading day before vs. one trading day after each earnings release.
| Period | Report Date | EPS Beat/Miss | Price Before | Price After | 1D Reaction |
|---|---|---|---|---|---|
| ▼ Q2 FY2026 | May 5, 2026 | -37.0% | $4.60 | $4.52 | -1.74% |
| ▲ Q1 FY2026 | Mar 12, 2026 | +13.9% | $3.53 | $3.52 | -0.28% |
| ▲ Q4 FY2025 | Nov 6, 2025 | +9.2% | $3.00 | $3.16 | +5.33% |
| ▲ Q3 FY2025 | Aug 12, 2025 | +7.3% | $2.03 | $2.00 | -1.48% |
| ▲ Q2 FY2025 | May 6, 2025 | +9.8% | $2.51 | $2.23 | -11.16% |
| ▼ Q1 FY2025 | Mar 10, 2025 | -59.3% | $5.02 | $4.96 | -1.20% |
| ▼ Q4 FY2024 | Nov 7, 2024 | -13.4% | $16.99 | $17.19 | +1.18% |
| ▼ Q3 FY2024 | Aug 13, 2024 | -60.0% | $13.40 | $13.80 | +2.99% |
Q2 FY2026-1.74%
Report Date
May 5, 2026
EPS Beat/Miss
-37.0%
Price Before
$4.60
Price After
$4.52
Q1 FY2026-0.28%
Report Date
Mar 12, 2026
EPS Beat/Miss
+13.9%
Price Before
$3.53
Price After
$3.52
Q4 FY2025+5.33%
Report Date
Nov 6, 2025
EPS Beat/Miss
+9.2%
Price Before
$3.00
Price After
$3.16
Q3 FY2025-1.48%
Report Date
Aug 12, 2025
EPS Beat/Miss
+7.3%
Price Before
$2.03
Price After
$2.00
Q2 FY2025-11.16%
Report Date
May 6, 2025
EPS Beat/Miss
+9.8%
Price Before
$2.51
Price After
$2.23
Q1 FY2025-1.20%
Report Date
Mar 10, 2025
EPS Beat/Miss
-59.3%
Price Before
$5.02
Price After
$4.96
Q4 FY2024+1.18%
Report Date
Nov 7, 2024
EPS Beat/Miss
-13.4%
Price Before
$16.99
Price After
$17.19
Q3 FY2024+2.99%
Report Date
Aug 13, 2024
EPS Beat/Miss
-60.0%
Price Before
$13.40
Price After
$13.80
Avg Beat Reaction-1.90%
Avg Miss Reaction+0.31%
Beat Rate4 / 8 quarters
Largest Move-11.16% (Q2 FY2025)
Data: FMP /historical-price-eod/full · field: close
About Earnings & Data Methodology
Data source: Financial Modeling Prep (FMP) | Updated: Hourly | Surprise%: (Actual − Estimate) / |Estimate| × 100 | Fiscal year: OKUR ends December
OnKure Therapeutics, Inc. (OKUR) most recently reported earnings on May 5, 2026 for Q2 FY2026, posting EPS of $-1.11 — missing the analyst consensus of $-0.81 by -37.0%. The next OKUR earnings date is expected around September 1, 2026.
Each quarter, investors track OKUR earnings for signals on forward guidance and business momentum. For longer-term revenue trends, see the Revenue tab. OKUR revenue tab →
Earnings Glossary
EPS (Earnings Per Share)
Net income ÷ diluted shares outstanding. The primary metric analysts use to gauge quarterly profitability.
Earnings Surprise %
(Actual − Estimate) / |Estimate| × 100. Positive = Beat. Negative = Miss.
Beat / Miss / In-Line
Beat = Actual ≥ Estimate. Miss = Actual < Estimate. In-Line = within ±1%.
BMO / AMC
Before Market Open / After Market Close. Two windows when companies typically release results.
Fiscal Quarter
OKUR's fiscal year ends in December. Fiscal quarters may not align with calendar quarters.
Analyst Consensus
Average EPS/Revenue forecast across all covering analysts. More analysts = more reliable estimate.
Figures tie to FMP earnings calendar, estimates, and SEC 10-Q/10-K filings where noted.
Frequently asked questions
OKUR earnings · 5 questionsOnKure Therapeutics, Inc.'s next earnings report is expected around September 1, 2026. OKUR typically reports quarterly — approximately every three months. The exact date is confirmed by the company 2–4 weeks before the release. Time is currently TBD; OKUR historically reports after market close (AMC).
OKUR earnings datewhen is OKUR earningsOKUR next earnings datewhen does OKUR report earningsOKUR earnings calendar
▸ Source: FMP · OnKure Therapeutics, Inc. SEC filings · US GAAP · OnKure Therapeutics, Inc. SEC 10-K & 10-Q filings · US GAAP · Updated: Jun 9, 2026